Masitinib for ALS: A trial testing a new drug with standard care
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests if adding masitinib to standard ALS care (riluzole) can slow disease progression. It's for people with a specific rate of decline and who meet certain health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of probable or definite ALS (using standard criteria).
- You must be between 18 and 80 years old, with either family or sporadic ALS.
- You must be taking a stable dose of riluzole (100 mg/day) for at least 30 days before the trial starts.
- Your first ALS symptom must have started within the last 36 months.
- Your ALS progression rate must be between 0.3 and 1.1 points per month on a standard function scale.
- You must have adequate lung function (FVC at least 70% of predicted) and not have certain other serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.
This study tests a gentle, non-invasive magnetic stimulation applied to the head to see if it can slow the progression of ALS. It uses a special device that creates a static magnetic field, and researchers will also look for biomarkers in your body that may help predict how the disease will progress.
This pilot trial tests whether a dietary supplement called HMB (beta-hydroxy-beta-methylbutyrate) can help lower a protein called IGFBP7 that may be linked to ALS progression. If it works, this approach might slow down muscle weakness in people with ALS.
This trial tests whether a transplant of healthy gut bacteria (called a microbiome transplant) can slow down ALS in people whose disease is progressing rapidly. It aims to see if changing the gut environment can help with symptoms and quality of life.
This Phase 2 trial tests a treatment meant to improve “energy production” in people with ALS. It aims to see whether increasing mitochondrial (cell energy) capacity can help ALS symptoms or progression.
This Phase 3 study tests whether masitinib works better than an inactive pill (placebo) to slow ALS progression and keep it safe. It is meant for people recently diagnosed with ALS who meet specific breathing and function score requirements.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.